LL-37 5 MG

LL-37 5 mg – Peptide Hubs

LL-37 is a naturally occurring antimicrobial peptide (AMP) that plays a vital role in the human innate immune system. As the only known human cathelicidin peptide, LL-37 is involved in bacterial, viral, and fungal defense as well as in tissue healing and inflammation modulation. Peptide Hubs provides high-purity LL-37 in a 5 mg lyophilized vial for use in immune, dermatological, and regenerative research.

Mechanism of Action

LL-37 acts by disrupting the membranes of pathogens through electrostatic interactions, leading to bacterial cell lysis. Beyond antimicrobial activity, LL-37 also influences chemotaxis, angiogenesis, and epithelial cell proliferation, making it relevant in wound healing and immune surveillance models. For more information, see this NIH article on LL-37 functions in immunity.

Research Applications

• Broad-spectrum antimicrobial activity studies
• Skin repair and chronic wound healing models
• Respiratory epithelial defense research (e.g., sinusitis, lung injury)
• Modulation of inflammatory cytokines and immune response

LL-37 is often co-researched with GHK Basic for epithelial and collagen regeneration, or Chonluten for respiratory inflammation studies. Some researchers explore combined protocols with L-Glutathione for oxidative defense, or B7-33 for tissue remodeling in fibrotic conditions.

Suggested Experimental Use

• Dosage: 100–500 mcg daily depending on study
• Administration: Subcutaneous or intradermal injection
• Cycle Duration: 1–4 weeks in immune or tissue repair models

Stacking Recommendations

• DSIP – for immune support during recovery and anti-inflammatory balance
• FOX04-DRI – in aging-related immunomodulatory pathways
• Cardiogen – for vascular healing under oxidative stress models
• Semaglutide – for studies involving immune-metabolic regulation

Safety & Legal Status

LL-37 is a synthetic peptide intended strictly for **research use only** and is not FDA-approved. It shows no toxicity, does not aromatize, and has no hormonal interaction. It is well tolerated in skin, immune, and epithelial models. For active trials and data, refer to ClinicalTrials.gov.

Frequently Asked Questions